Circular RNAs (circRNAs) constitute an abundant class of covalently closed noncoding RNA molecules that are formed by backsplicing from eukaryotic protein-coding genes. Recent studies have shown that circRNAs can act as microRNA or protein decoys, as well as transcriptional regulators. However, the functions of most circRNAs are still poorly understood. Because circRNA sequences overlap with their linear parent transcripts, depleting specific circRNAs without affecting host gene expression remains a challenge. In this study, we assessed the utility of LNA-modified antisense oligonucleotides (ASOs) to knock down circRNAs for loss-of-function studies. We found that, while most RNase H-dependent gapmer ASOs mediate effective knockdown of their target circRNAs, some gapmers reduce the levels of the linear parent transcript. The circRNA targeting specificity can be enhanced using design-optimized gapmer ASOs, which display potent and specific circRNA knockdown with a minimal effect on the host genes. In summary, our results demonstrate that LNA-modified ASOs complementary to backsplice-junction sequences mediate robust knockdown of circRNAs in vitro and, thus, represent a useful tool to explore the biological roles of circRNAs in loss-of-function studies in cultured cells and animal models.
Get full access to this article
View all access options for this article.
References
1.
JeckWR, SorrentinoJA, WangK, SlevinMK, BurdCE, LiuJ, MarzluffWF and SharplessNE. (2013). Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA, 19:141–157.
2.
MemczakS, JensM, ElefsiniotiA, TortiF, KruegerJ, RybakA, MaierL, MackowiakSD, GregersenLH, et al. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature, 495:333–338.
3.
SalzmanJ, GawadC, WangPL, LacayoN and Brown.PO (2012). Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One, 7:e30733.
4.
SzaboL and SalzmanJ. (2016). Detecting circular RNAs: bioinformatic and experimental challenges. Nat Rev Genet, 17:679–692.
5.
GlažarP, PapavasileiouP and RajewskyN. (2014). circBase: a database for circular RNAs. RNA, 20:1666–1670.
6.
LiX, YangL and ChenLL. (2018). The biogenesis, functions, and challenges of circular RNAs. Mol Cell, 71:428–442.
7.
HoldtLM, KohlmaierA and TeupserD. (2018). Molecular functions and specific roles of circRNAs in the cardiovascular system. Noncoding RNA Res, 3:75–98.
ConnSJ, PillmanKA, ToubiaJ, ConnVM, SalmanidisM, PhillipsCA, RoslanS, SchreiberAW, GregoryPA and GoodallGJ. (2015). The RNA binding protein quaking regulates formation of circRNAs. Cell, 160:1125–1134.
14.
ErrichelliL, Dini ModiglianiS, LaneveP, ColantoniA, LegniniI, CapautoD, RosaA, De SantisR, ScarfòR, et al. (2017). FUS affects circular RNA expression in murine embryonic stem cell-derived motor neurons. Nat Commun, 8:14741.
15.
LiX, LiuCX, XueW, ZhangY, JiangS, YinQF, WeiJ, YaoRW, YangL and Chen.LL (2017). Coordinated circRNA Biogenesis and Function with NF90/NF110 in Viral Infection. Mol Cell 67:214–227.e217.
16.
LiZ, HuangC, BaoC, ChenL, LinM, WangX, ZhongG, YuB, HuW, et al. (2015). Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol, 22:256–264.
17.
ZhangY, ZhangXO, ChenT, XiangJF, YinQF, XingYH, ZhuS, YangL and ChenLL. (2013). Circular intronic long noncoding RNAs. Mol Cell, 51:792–806.
18.
LiangD, TatomerDC, LuoZ, WuH, YangL, ChenLL, CherryS and Wilusz.JE (2017). The output of protein-coding genes shifts to circular RNAs when the pre-mRNA processing machinery is limiting. Mol Cell 68:940–954.e943.
19.
Wilusz JE. (2018). A 360° view of circular RNAs: from biogenesis to functions. Wiley Interdiscip Rev RNA, 9:e1478.
20.
HansenTB, JensenTI, ClausenBH, BramsenJB, FinsenB, DamgaardCK and KjemsJ. (2013). Natural RNA circles function as efficient microRNA sponges. Nature, 495:384–388.
21.
PiweckaM, GlažarP, Hernandez-MirandaLR, MemczakS, WolfSA, Rybak-WolfA, FilipchykA, KlironomosF, Cerda JaraCA, et al. (2017). Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. Science, 357:eaam8526.
22.
LiY, GeYZ, XuL and Jia.R (2020). Circular RNA ITCH: a novel tumor suppressor in multiple cancers. Life Sci, 254:117176.
23.
GuoJU, AgarwalV, GuoH and Bartel.DP (2014). Expanded identification and characterization of mammalian circular RNAs. Genome Biol, 15:409.
24.
JeckWR and SharplessNE. (2014). Detecting and characterizing circular RNAs. Nat Biotechnol, 32:453–461.
25.
DuWW, YangW, ChenY, WuZK, FosterFS, YangZ, LiX, and YangBB. (2017). Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J, 38:1402–1412.
26.
BurdCE, JeckWR, LiuY, SanoffHK, WangZ and Sharpless.NE (2010). Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet, 6:e1001233.
27.
HoldtLM, StahringerA, SassK, PichlerG, KulakNA, WilfertW, KohlmaierA, HerbstA, NorthoffBH, et al. (2016). Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun, 7:12429.
28.
AbdelmohsenK, PandaAC, MunkR, GrammatikakisI, DudekulaDB, DeS, KimJ, NohJH, KimKM, et al. (2017). Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol, 14:361–369.
29.
ConnVM, HugouvieuxV, NayakA, ConosSA, CapovillaG, CildirG, JourdainA, TergaonkarV, SchmidM, et al. (2017). A circRNA from SEPALLATA3 regulates splicing of its cognate mRNA through R-loop formation. Nat Plants, 3:17053.
30.
LegniniI, Di TimoteoG, RossiF, MorlandoM, BrigantiF, SthandierO, FaticaA, SantiniT, AndronacheA, et al. (2017). Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol Cell 66:22–37.e29.
31.
PamudurtiNR, BartokO, JensM, Ashwal-FlussR, StottmeisterC, RuheL, HananM, WylerE, Perez-HernandezD, et al. (2017). Translation of circRNAs. Mol Cell 66:9–21.e27.
32.
YangY, FanX, MaoM, SongX, WuP, ZhangY, JinY, YangY, ChenLL, et al. (2017). Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res, 27:626–641.
33.
LiangWC, WongCW, LiangPP, ShiM, CaoY, RaoST, TsuiSK, WayeMM, ZhangQ, et al. (2019). Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol, 20:84.
34.
HoldtLM, KohlmaierA and Teupser.D (2018). Circular RNAs as therapeutic agents and targets. Front Physiol, 9:1262.
35.
VoJN, CieslikM, ZhangY, ShuklaS, XiaoL, ZhangY, WuYM, DhanasekaranSM, EngelkeCG, et al. (2019). The landscape of circular RNA in cancer. Cell 176:869–881.e813.
36.
SettenRL, RossiJJ and HanSP. (2019). The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov, 18:421–446.
37.
ZhengQ, BaoC, GuoW, LiS, ChenJ, ChenB, LuoY, LyuD, LiY, et al. (2016). Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun, 7:11215.
38.
PatopIL and KadenerS. (2018). circRNAs in Cancer. Curr Opin Genet Dev, 48:121–127.
39.
ChenS, ZhouY, ChenY and GuJ. (2018). fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics, 34:i884–i890.
RobinsonMD, McCarthyDJ and SmythGK. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26:139–140.
DavisCA, HitzBC, SloanCA, ChanET, DavidsonJM, GabdankI, HiltonJA, JainK, BaymuradovUK, et al. (2018). The encyclopedia of DNA elements (ENCODE): data portal update. Nucleic Acids Res, 46:D794–D801.
44.
HacisuleymanE, GoffLA, TrapnellC, WilliamsA, Henao-MejiaJ, SunL, McClanahanP, HendricksonDG, SauvageauM, et al. (2014). Topological organization of multichromosomal regions by the long intergenic noncoding RNA Firre. Nat Struct Mol Biol, 21:198–206.
45.
YangF, DengX, MaW, BerletchJB, RabaiaN, WeiG, MooreJM, FilippovaGN, XuJ, et al. (2015). The lncRNA Firre anchors the inactive X chromosome to the nucleolus by binding CTCF and maintains H3K27me3 methylation. Genome Biol, 16:52.
46.
SunL, GoffLA, TrapnellC, AlexanderR, LoKA, HacisuleymanE, SauvageauM, Tazon-VegaB, KelleyDR, et al. (2013). Long noncoding RNAs regulate adipogenesis. Proc Natl Acad Sci U S A, 110:3387–3392.
47.
LewandowskiJP, LeeJC, HwangT, SunwooH, GoldsteinJM, GroffAF, ChangNP, MallardW, WilliamsA, et al. (2019). The Firre locus produces a trans-acting RNA molecule that functions in hematopoiesis. Nat Commun, 10:5137.
48.
DevesonIW, BrunckME, BlackburnJ, TsengE, HonT, ClarkTA, ClarkMB, CrawfordJ, DingerME, et al. (2018). Universal alternative splicing of noncoding exons. Cell Syst 6:245–255.e245.
49.
IzuoguOG, AlhasanAA, MelloughC, CollinJ, GallonR, HyslopJ, MastrorosaFK, EhrmannI, LakoM, et al. (2018). Analysis of human ES cell differentiation establishes that the dominant isoforms of the lncRNAs RMST and FIRRE are circular. BMC Genomics, 19:276.
50.
MiyagawaR, TanoK, MizunoR, NakamuraY, IjiriK, RakwalR, ShibatoJ, MasuoY, MayedaA, et al. (2012). Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles. RNA, 18:738–751.
51.
TripathiV, EllisJD, ShenZ, SongDY, PanQ, WattAT, FreierSM, BennettCF, SharmaA, et al. (2010). The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell, 39:925–938.
52.
KongR, ZhangEB, YinDD, YouLH, XuTP, ChenWM, XiaR, WanL, SunM, et al. (2015). Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer, 14:82.
53.
Alvarez-DominguezJR, WintherS, HansenJB, LodishHF and Knoll.M (2022). An adipose lncRAP2-Igf2bp2 complex enhances adipogenesis and energy expenditure by stabilizing target mRNAs. iScience, 25:103680.
54.
PedersenL, HagedornPH and KochT. (2019). Identifying suitable target regions and analyzing off-target effects of therapeutic oligonucleotides. Methods Mol Biol, 2036:261–282.
HanJ, LiW, ZhangJ, GuanY, HuangY and LiX. (2022). Mechanism of circHIPK3-miRNA-124-3p/miRNA-148b-3p-mediated inflammatory responses and cell senescence in candida albicans-induced septic acute kidney injury. Gerontology, 68:1145–1165.
57.
YuQ, ChenW, LiY, HeJ, WangY, YangS and ZhouJ. (2022). The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis. Bioengineered, 13:4717–4729.
58.
Chen LL. (2016). The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol, 17:205–211.
59.
XiaoMS, AiY and WiluszJE. (2020). Biogenesis and functions of circular RNAs come into focus. Trends Cell Biol, 30:226–240.
60.
GuriaA, SharmaP, NatesanS and Pandi.G (2019). Circular RNAs-the road less traveled. Front Mol Biosci, 6:146.
XiaoMS and WiluszJE. (2019). An improved method for circular RNA purification using RNase R that efficiently removes linear RNAs containing G-quadruplexes or structured 3′ ends. Nucleic Acids Res, 47:8755–8769.
63.
TsengYY, MoriarityBS, GongW, AkiyamaR, TiwariA, KawakamiH, RonningP, ReulandB, GuentherK, et al. (2014). PVT1 dependence in cancer with MYC copy-number increase. Nature, 512:82–86.
64.
ZhaoJ, DuP, CuiP, QinY, HuC, WuJ, ZhouZ, ZhangW, QinL and HuangG. (2018). LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene, 37:4094–4109.
65.
Kun-PengZ, Xiao-LongM and Chun-LinZ. (2018). Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci, 14:321–330.
66.
HuJ, HanQ, GuY, MaJ, McGrathM, QiaoF, ChenB, SongC, and GeZ. (2018). Circular RNA PVT1 expression and its roles in acute lymphoblastic leukemia. Epigenomics, 10:723–732.
67.
ChenJ, LiY, ZhengQ, BaoC, HeJ, ChenB, LyuD, ZhengB, XuY, et al. (2017). Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett, 388:208–219.
68.
VerduciL, FerraiuoloM, SacconiA, GanciF, VitaleJ, ColomboT, PaciP, StranoS, MacinoG, et al. (2017). The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biol, 18:237.
69.
LuY, LiuX, XieM, LiuM, YeM, LiM, ChenXM, LiX and ZhouR. (2017). The NF-κB-responsive long noncoding RNA FIRRE regulates posttranscriptional regulation of inflammatory gene expression through interacting with hnRNPU. J Immunol, 199:3571–3582.
70.
GuarnerioJ, BezziM, JeongJC, PaffenholzSV, BerryK, NaldiniMM, Lo-CocoF, TayY, BeckAH and PandolfiPP. (2016). Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations. Cell, 165:289–302.
71.
KristensenLS, AndersenMS, StagstedLVW, EbbesenKK, HansenTB and KjemsJ. (2019). The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet, 20:675–691.
72.
LiangY, SongX, LiY, MaT, SuP, GuoR, ChenB, ZhangH, SangY, et al. (2019). Targeting the circBMPR2/miR-553/USP4 axis as a potent therapeutic approach for breast cancer. Mol Ther Nucleic Acids, 17:347–361.
73.
LennoxKA and BehlkeMA. (2016). Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res, 44:863–877.
74.
WattsJK and CoreyDR. (2012). Silencing disease genes in the laboratory and the clinic. J Pathol, 226:365–379.
75.
AbudayyehOO, GootenbergJS, EssletzbichlerP, HanS, JoungJ, BelantoJJ, VerdineV, CoxDBT, KellnerMJ, et al. (2017). RNA targeting with CRISPR-Cas13. Nature, 550:280–284.
76.
KonermannS, LotfyP, BrideauNJ, OkiJ, ShokhirevMN and Hsu.PD (2018). Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173:665–676.e614.
77.
LiS, LiX, XueW, ZhangL, YangLZ, CaoSM, LeiYN, LiuCX, GuoSK, et al. (2021). Screening for functional circular RNAs using the CRISPR-Cas13 system. Nat Methods, 18:51–59.
78.
KhvorovaA and WattsJK. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol, 35:238–248.
79.
CrookeST, WangS, VickersTA, ShenW and LiangXH. (2017). Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol, 35:230–237.
80.
ShenX and CoreyDR. (2018). Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res, 46:1584–1600.
81.
AlexanderVJ, XiaS, HurhE, HughesSG, O'DeaL, GearyRS, WitztumJL and TsimikasS. (2019). N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J, 40:2785–2796.
82.
TardifJC, Karwatowska-ProkopczukE, AmourES, BallantyneCM, ShapiroMD, MoriartyPM, BaumSJ, HurhE, BartlettVJ, et al. (2022). Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J, 43:1401–1412.
83.
TsimikasS, Karwatowska-ProkopczukE, Gouni-BertholdI, TardifJC, BaumSJ, Steinhagen-ThiessenE, ShapiroMD, StroesES, MoriartyPM, et al. (2020). Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med, 382:244–255.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
